Cargando…

Reduction of circulating FABP4 level by treatment with omega-3 fatty acid ethyl esters

BACKGROUND: Fatty acid-binding protein 4 (FABP4/A-FABP/aP2) mainly expressed in adipocytes is secreted and acts as an adipokine. Increased circulating FABP4 level is associated with obesity, insulin resistance and atherosclerosis. However, little is known about the modulation of serum FABP4 level by...

Descripción completa

Detalles Bibliográficos
Autores principales:	Furuhashi, Masato, Hiramitsu, Shinya, Mita, Tomohiro, Omori, Akina, Fuseya, Takahiro, Ishimura, Shutaro, Watanabe, Yuki, Hoshina, Kyoko, Matsumoto, Megumi, Tanaka, Marenao, Moniwa, Norihito, Yoshida, Hideaki, Ishii, Junnichi, Miura, Tetsuji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4710044/ https://www.ncbi.nlm.nih.gov/pubmed/26754658 http://dx.doi.org/10.1186/s12944-016-0177-8

Ejemplares similares

Possible Increase in Serum FABP4 Level Despite Adiposity Reduction by Canagliflozin, an SGLT2 Inhibitor
por: Furuhashi, Masato, et al.
Publicado: (2016)

Ectopic Fatty Acid–Binding Protein 4 Expression in the Vascular Endothelium is Involved in Neointima Formation After Vascular Injury
por: Fuseya, Takahiro, et al.
Publicado: (2017)

Serum FABP5 concentration is a potential biomarker for residual risk of atherosclerosis in relation to cholesterol efflux from macrophages
por: Furuhashi, Masato, et al.
Publicado: (2017)

Reduction of endoplasmic reticulum stress inhibits neointima formation after vascular injury
por: Ishimura, Shutaro, et al.
Publicado: (2014)

Circulating Levels of Fatty Acid-Binding Protein Family and Metabolic Phenotype in the General Population
por: Ishimura, Shutaro, et al.
Publicado: (2013)

Urinary Excretion of Fatty Acid-Binding Protein 4 is Associated with Albuminuria and Renal Dysfunction
por: Okazaki, Yusuke, et al.
Publicado: (2014)

Elevated circulating FABP4 concentration predicts cardiovascular death in a general population: a 12-year prospective study
por: Saito, Norie, et al.
Publicado: (2021)

Elevation of circulating fatty acid-binding protein 4 is independently associated with left ventricular diastolic dysfunction in a general population
por: Fuseya, Takahiro, et al.
Publicado: (2014)

Elevation of Fatty Acid-Binding Protein 4 Is Predisposed by Family History of Hypertension and Contributes to Blood Pressure Elevation
por: Ota, Hideki, et al.
Publicado: (2012)

A Case of Crescentic Glomerulonephritis Complicated with Hypocomplementemic Urticarial Vasculitis Syndrome and ANCA-Associated Vasculitis
por: Tanaka, Marenao, et al.
Publicado: (2017)

Increased LDL-cholesterol level is associated with deterioration of renal function in males
por: Osanami, Arata, et al.
Publicado: (2022)

Independent links between plasma xanthine oxidoreductase activity and levels of adipokines
por: Furuhashi, Masato, et al.
Publicado: (2019)

Significance of urinary fatty acid-binding protein 4 level as a possible biomarker for the identification of minimal change disease in patents with nephrotic-range proteinuria
por: Tanaka, Marenao, et al.
Publicado: (2020)

Low urine pH predicts new onset of diabetes mellitus during a 10‐year period in men: BOREAS‐DM1 study
por: Higashiura, Yukimura, et al.
Publicado: (2020)

Transcriptome and Metabolome Analyses in Exogenous FABP4- and FABP5-Treated Adipose-Derived Stem Cells
por: Yamamoto, Tokunori, et al.
Publicado: (2016)

Lipid Chaperones and Metabolic Inflammation
por: Furuhashi, Masato, et al.
Publicado: (2011)

Differential regulation of hypoxanthine and xanthine by obesity in a general population
por: Furuhashi, Masato, et al.
Publicado: (2020)

Serum Fatty Acid-Binding Protein 4 Is a Predictor of Cardiovascular Events in End-Stage Renal Disease
por: Furuhashi, Masato, et al.
Publicado: (2011)

High level of fatty liver index predicts new onset of diabetes mellitus during a 10-year period in healthy subjects
por: Higashiura, Yukimura, et al.
Publicado: (2021)

Fatty liver index is independently associated with deterioration of renal function during a 10-year period in healthy subjects
por: Takahashi, Satoko, et al.
Publicado: (2021)

Elevated Fatty Liver Index Is Independently Associated With New Onset of Hypertension During a 10‐Year Period in Both Male and Female Subjects
por: Higashiura, Yukimura, et al.
Publicado: (2021)

Differential Phenotypes in Perivascular Adipose Tissue Surrounding the Internal Thoracic Artery and Diseased Coronary Artery
por: Numaguchi, Ryosuke, et al.
Publicado: (2019)

Fatty Acid-Binding Protein 4 (FABP4): Pathophysiological Insights and Potent Clinical Biomarker of Metabolic and Cardiovascular Diseases
por: Furuhashi, Masato, et al.
Publicado: (2015)

Empagliflozin attenuates acute kidney injury after myocardial infarction in diabetic rats
por: Kuno, Atsushi, et al.
Publicado: (2020)

Uses and benefits of omega-3 ethyl esters in patients with cardiovascular disease
por: Levantesi, Giacomo, et al.
Publicado: (2010)

Adverse effects of ethyl esters or oxidation products in omega-3 preparations?
por: Rupp, Heinz, et al.
Publicado: (2014)

Independent and Distinct Associations of FABP4 and FABP5 With Metabolic Parameters in Type 2 Diabetes Mellitus
por: Furuhashi, Masato, et al.
Publicado: (2020)

Microalgal feedstock for the production of omega-3 fatty acid ethyl esters and ɛ-polylysine
por: Sivaramakrishnan, Ramachandran, et al.
Publicado: (2021)

Potential differential effects of renin-angiotensin system inhibitors on SARS-CoV-2 infection and lung injury in COVID-19
por: Furuhashi, Masato, et al.
Publicado: (2020)

Understanding hypertriglyceridemia in women: clinical impact and management with prescription omega-3-acid ethyl esters
por: Dayspring, Thomas D
Publicado: (2011)

Study protocol of the PROUD48 study comparing the effects of pemafibrate and omega-3 fatty acid ethyl esters on ApoB-48 in statin-treated patients with dyslipidaemia: a prospective, multicentre, open-label, randomised, parallel group trial in Japan
por: Takeda, Yasutaka, et al.
Publicado: (2022)

Retrospective Case Series of Patients with Diabetes or Prediabetes Who Were Switched from Omega-3-Acid Ethyl Esters to Icosapent Ethyl
por: Hassan, Amir, et al.
Publicado: (2014)

A Review of Omega-3 Ethyl Esters for Cardiovascular Prevention and Treatment of Increased Blood Triglyceride Levels
por: von Schacky, Clemens
Publicado: (2006)

ODP155 Successful Treatment of PEG-Asparaginase Related Hypertriglyceridemia with Omega-3 Acid Ethyl Esters
por: Radovanovic, Natasa, et al.
Publicado: (2022)

Effect of Omega-3 Fatty Acid Ethyl Esters on the Oxylipin Composition of Lipoproteins in Hypertriglyceridemic, Statin-Treated Subjects
por: Newman, John W., et al.
Publicado: (2014)

New Therapy Using Omega-3-Acid Ethyl Esters for Decubitus Ulcers and Stasis Dermatitis: A Case Report
por: Nagai, Kazuki, et al.
Publicado: (2014)

CMPF, a Metabolite Formed Upon Prescription Omega-3-Acid Ethyl Ester Supplementation, Prevents and Reverses Steatosis
por: Prentice, Kacey J., et al.
Publicado: (2017)

Comparison of pharmacokinetics of omega-3 fatty acid supplements in monoacylglycerol or ethyl ester in humans: a randomized controlled trial
por: Chevalier, Laurie, et al.
Publicado: (2020)

Reply to the comments of Naharci et al. on “Circulating level of fatty acid‐binding protein 4 is an independent predictor of metabolic dysfunction‐associated fatty liver disease in middle‐aged and elderly individuals”
por: Tanaka, Marenao, et al.
Publicado: (2022)

Patient with Hypertriglyceridemia, Type 2 Diabetes, and Chronic Kidney Disease Treated with Atorvastatin and Omega-3 Fatty Acid Ethyl Esters
por: Athyros, Vasilios G, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_g93977vuaqd1f4kcl8e31gt77n